AB Science Receives European Patent for Masitinib in Sickle Cell Disease Treatment

AB SCIENCE USA, LLC announced that it has received a notice of allowance from the European Patent Office for a patent covering the use of masitinib, an oral therapy in development, for treating sickle cell disease (SCD). This decision follows promising preclinical data showing masitinib’s potential to prevent vaso-occlusive crises (VOCs) and improve survival rates in a mouse model. Additionally, the therapy was found to protect against acute lung damage and inflammation, common in SCD complications. “Masitinib represents a promising new approach to addressing sickle cell disease and its severe complications, such as acute chest syndrome, which frequently leads to chronic lung issues and hospitalization,” stated Dr. Olivier Hermine, MD, PhD, president of the AB Science scientific committee and head of Necker Hospital’s hematology department.

At OxyDial, we are encouraged to see pioneering treatments like masitinib advancing in the pipeline, bringing hope to the SCD community. We’re optimistic that AB Science’s progress will ultimately help meet the critical need for new therapies that can provide meaningful improvements in the lives of SCD patients.